Vaxcyte (PCVX) Operating Expenses (2019 - 2026)

Vaxcyte (PCVX) has reported Operating Expenses for 8 consecutive years, with $345.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 91.3% year-over-year to $345.8 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 71.22% YoY), while the FY2025 annual figure was $923.7 million, up 62.18% from the prior year.
• Operating Expenses grew to $345.8 million in Q1 2026 per PCVX's latest filing, from $274.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $345.8 million in Q1 2026 and bottomed at $39.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $149.4 million across 5 years, with a median of $139.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 190.07% — and 2024, when it decreased 17.55%.
• Vaxcyte's Operating Expenses stood at $86.6 million in 2022, then surged by 127.18% to $196.7 million in 2023, then fell by 17.55% to $162.2 million in 2024, then soared by 69.13% to $274.3 million in 2025, then grew by 26.09% to $345.8 million in 2026.
• Business Quant data shows PCVX's Operating Expenses at $345.8 million in Q1 2026, $274.3 million in Q4 2025, and $242.4 million in Q3 2025.